David Rizzieri
Medical Oncology · Charlotte, NCNPI 1043346877
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $550,279 of the $713,515 with a category attached, or 77.1%. 30 manufacturers reported payments, led by Incyte Corporation at 42.6% of the total. Reporting peaked in 2020 at $208,738 and has fallen 99.7% since, to $633 in 2025. Among medical oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $1495.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$304K
- Gilead$141K
- Stemline Therapeutics Inc.$80K
- Seagen Inc.$40K
- Sanofi$40K
- Jazz Pharmaceuticals Inc.$28K
- plus $81K from 24 others
Across 157 payments — averaging $6639.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$381K
- Otsuka Pharmaceutical Co., Ltd.$240K
- Pfizer$116K
- Astellas Pharma Global Development$106K
- Acrotech Biopharma Inc.$64K
- Amgen$41K
- plus $94K from 7 others
What the payments were for
- Consulting fees$96,17513%
- Speaking & faculty fees$550,27977%
- Travel & lodging$59,3968%
- Food & beverage$7,6601%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 180 | $303,809 |
| Gilead(2 entities) | 67 | $140,699 |
| Stemline Therapeutics Inc. | 67 | $79,863 |
| Seagen Inc. | 32 | $40,010 |
| Sanofi | 26 | $39,850 |
| Jazz Pharmaceuticals Inc. | 17 | $28,268 |
| Astellas Pharma US Inc | 13 | $14,357 |
| Aurobindo Pharma USA, Inc. | 7 | $14,064 |
| Pfizer | 8 | $11,458 |
| Agios Pharmaceuticals, Inc. | 11 | $10,444 |
| Spectrum Pharmaceuticals Inc. | 5 | $7,761 |
| Bristol Myers Squibb | 6 | $6,703 |
| AbbVie | 11 | $6,432 |
| Karyopharm Therapeutics Inc. | 2 | $2,063 |
| Kadmon Pharmaceuticals LLC | 2 | $1,635 |
| Bayer | 1 | $1,125 |
| Novartis | 3 | $1,085 |
| Acceleron Pharma, Inc. | 1 | $845 |
| Epizyme, Inc. | 1 | $675 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $600 |
| Amgen | 1 | $550 |
| GSK | 4 | $402 |
| Genentech USA, Inc. | 3 | $310 |
| Genentech, Inc. | 1 | $150 |
| Celularity Inc. | 1 | $111 |
| Intuitive Surgical | 1 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $65 |
| Medtronic | 1 | $63 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Eisai Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$713,515 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $41 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Charlotte
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Edward KimCharlotte$188K
- Kathryn MilehamCharlotte$110K
- Antoinette TanCharlotte$89K
- Jimmy HwangCharlotte$64K
- Ashley SumrallCharlotte$55K
- Obiageli OgbataCharlotte$26K
- Daniel CarrizosaCharlotte$20K
- Daniel HaggstromCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.